Anderson P. Use of Respimat® Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-259.
Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12 Suppl 1:S19-S24.
Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of ESPIMAT®inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565-1577.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Actualizado mayo de 2024. Disponible en: www.ginasthma.org
Szefler SJ, et al. Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma, Independent of T2 Phenotype. J Allergy Clin Immunol Pract. 2019;7(7):2286-2295.e4.
Szefler SJ, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140(5):1277-1287.
Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312-1319.